Viatris: Number of Employees 2010-2024 | VTRS
Interactive chart of Viatris (VTRS) annual worldwide employee count from 2010 to 2024.
- Viatris total number of employees in 2023 was 38,000, a 2.7% increase from 2022.
- Viatris total number of employees in 2022 was 37,000, a 0% decline from 2021.
- Viatris total number of employees in 2021 was 37,000, a 17.78% decline from 2020.
- Viatris total number of employees in 2020 was 45,000, a 28.57% increase from 2019.
| Viatris Annual Employee Count | |
|---|---|
| 2023 | 38,000 |
| 2022 | 37,000 |
| 2021 | 37,000 |
| 2020 | 45,000 |
| 2019 | 35,000 |
| 2018 | 35,000 |
| 2017 | 35,000 |
| 2016 | 35,000 |
| 2015 | 35,000 |
| 2014 | 30,000 |
| 2013 | 20,000 |
| 2012 | 20,000 |
| 2011 | 18,000 |
| 2010 | 13,000 |
| 2009 | 15,500 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.488B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $89.358B | 11.09 |
| Cencora (COR) | United States | $46.783B | 17.59 |
| DiDi Global (DIDIY) | China | $22.844B | 0.00 |
| Natera (NTRA) | United States | $20.907B | 0.00 |
| ICON (ICLR) | Ireland | $16.343B | 14.56 |
| Avantor (AVTR) | United States | $15.048B | 22.56 |
| Revvity (RVTY) | United States | $14.408B | 25.03 |
| BioMerieux (BMXMF) | France | $13.788B | 0.00 |
| Solventum (SOLV) | United States | $12.699B | 0.00 |
| CochLear (CHEOY) | Australia | $12.341B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.485B | 29.54 |
| Doximity (DOCS) | United States | $10.029B | 59.03 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.551B | 0.00 |
| HealthEquity (HQY) | United States | $8.876B | 44.53 |
| Charles River Laboratories (CRL) | United States | $8.361B | 16.16 |
| Sonic Healthcare (SKHHY) | Australia | $8.244B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $6.136B | 31.28 |
| Bausch + Lomb (BLCO) | Canada | $6.118B | 28.46 |
| Organon (OGN) | United States | $4.054B | 4.09 |
| Sotera Health (SHC) | United States | $3.676B | 19.67 |
| BrightSpring Health Services (BTSG) | United States | $3.230B | 68.70 |
| Alignment Healthcare (ALHC) | United States | $2.795B | 0.00 |
| Concentras Parent (CON) | United States | $2.691B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.566B | 29.26 |
| Premier (PINC) | United States | $2.156B | 11.22 |
| PACS (PACS) | United States | $2.106B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.013B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.909B | 0.00 |
| Progyny (PGNY) | United States | $1.788B | 36.21 |
| GoodRx Holdings (GDRX) | United States | $1.742B | 45.70 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.658B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.565B | 0.00 |
| Agilon Health (AGL) | United States | $1.273B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.189B | 11.63 |
| CareDx (CDNA) | United States | $1.150B | 0.00 |
| Embecta (EMBC) | United States | $1.086B | 7.59 |
| AMN Healthcare Services Inc (AMN) | United States | $0.986B | 6.67 |
| Establishment Labs Holdings (ESTA) | $0.968B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.624B | 0.00 |
| SBC Medicals (SBC) | United States | $0.518B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.484B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.429B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.426B | 0.00 |
| DocGo (DCGO) | United States | $0.426B | 16.04 |
| Enhabit (EHAB) | United States | $0.402B | 34.74 |
| MultiPlan (MPLN) | United States | $0.260B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.239B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.217B | 0.00 |
| Beauty Health (SKIN) | United States | $0.216B | 0.00 |
| LifeMD (LFMD) | United States | $0.212B | 0.00 |
| Nutex Health (NUTX) | United States | $0.206B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.181B | 0.00 |
| Biodesix (BDSX) | United States | $0.167B | 0.00 |
| So-Young (SY) | China | $0.110B | 18.60 |
| ModivCare (MODV) | United States | $0.093B | 5.03 |
| Ascend Wellness Holdings (AAWH) | United States | $0.085B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 1.63 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| Oncology Institute (TOI) | United States | $0.042B | 0.00 |
| OncoCyte (OCX) | United States | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.032B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.025B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.025B | 0.00 |
| KindlyMD (KDLY) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |